TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31205156

Group type: EXPERIMENTAL
Intervention: 2.5% Patent Blue V (PB) for 10 minutes
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.06% Trypan Blue (TB) for 4 minutes
Number of subjects: 15
Study: 28263245

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin and Gentamicin
Number of subjects: 348

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 348
Study: 26572729

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard subnasal oxygen therapy
Number of subjects: 0
Study: 23178855

Group type: EXPERIMENTAL
Intervention: Pascal TargETEd Retinal photocoagulation (TRP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Minimally-traumatic panretinal photocoagulation (MT-PRP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-intensity PRP (SI-PRP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (TRP, MT-PRP, SI-PRP)
Number of subjects: 24
Study: 22045289

Group type: EXPERIMENTAL
Intervention: IV tPA and continuous TCD monitoring
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo monitoring
Number of subjects: 126
Study: 19117153

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered PO
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered IM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg administered IV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 40
Study: 17006858

Group type: EXPERIMENTAL
Intervention: 3 mg of bromazepam (B3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6 mg of bromazepam (B6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study: 15029039

Group type: EXPERIMENTAL
Intervention: C974P (0.25% fluid carbomer gel)
Number of subjects: 169

Group type: COMPARATOR
Intervention: C940 (conventional carbomer gel)
Number of subjects: 169
Study: 10875830

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8897086

Group type: EXPERIMENTAL
Intervention: Tenolol (100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tenormin (reference product)
Number of subjects: 24
Study: 1509999

Group type: EXPERIMENTAL
Intervention: Intravenous flecainide (2 mg/kg, maximum dose 150 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 6881917

Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Maternal folate levels
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 203
Study: 31800425

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (1.0 g before tourniquet inflation and again 3 hours later)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Topical TXA (3.0 g administered 5 minutes before final tourniquet release)
Number of subjects: 76
Study: 29032288

Group type: EXPERIMENTAL
Intervention: Social Skills Training Program for adults with WS (SSTP‐WS)
Number of subjects: 30
Study: 26293215

Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminders for 12 months
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminders
Number of subjects: 562
Study: 23892922

Group type: EXPERIMENTAL
Intervention: Pegylated G-CSF
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Unpegylated G-CSF
Number of subjects: 249

Group type: COMPARATOR
Intervention: Three G-CSF schedules (pegylated and unpegylated)
Number of subjects: 249
Study: 21350110

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg force titrated to 300 mg daily after 3 months) plus losartan (100 mg)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo plus losartan (100 mg)
Number of subjects: 599
Study: 19657288

Group type: EXPERIMENTAL
Intervention: Underwater treadmill (UTM) training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Land treadmill (LTM) training
Number of subjects: 57
Study: 17275781

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wait list (NL)
Number of subjects: 20
Study: 15165919

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10
Study: 11847727

Group type: EXPERIMENTAL
Intervention: Wrist band plus standard care plus next‐day phone call
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care plus next‐day phone call
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Wrist band
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Next‐day phone call
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients aged 65 years and older
Number of subjects: 61
Study: 9596323

Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks, twice daily) in patients with reduced ejection fraction (<40%)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (usual care) in patients with normal ventricular function (>50%)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (usual care) in patients with reduced ventricular function (<40%)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks, twice daily) in patients with normal ventricular function (>50%)
Number of subjects: 67
Study: 7851267

Group type: EXPERIMENTAL
Intervention: Urinary albumin/creatinine ratio
Number of subjects: 89
Study: 3378382

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP), 0.5 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: COMPARATOR
Intervention: L-tryptophan, 100 mg/kg (IV)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 52
Study: 31691621

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (160 mg dry extract with 4 mg of triterpene glycosides)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa
Number of subjects: 62
Study: 31116919

Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy
Number of subjects: 754

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy (per-protocol analysis)
Number of subjects: 754

Group type: COMPARATOR
Intervention: CPAP (per-protocol analysis)
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy and CPAP
Number of subjects: 754
Study: 28818450

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise intervention
Number of subjects: 128
Study: 24744399

Group type: EXPERIMENTAL
Intervention: Caregiving experience prior to hospice enrollment
Number of subjects: 0
Study: 23831174

Group type: EXPERIMENTAL
Intervention: Technology-based multi-component psychosocial intervention delivered in-home via videophone technology over 5 months.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Technology-based multi-component psychosocial intervention
Number of subjects: 110
Study: 21272743

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stenting (n = 100)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) (n = 101)
Number of subjects: 201
Study: 19198022

Group type: EXPERIMENTAL
Intervention: PEG solution and simethicone (Group 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PEG solution (Group 1)
Number of subjects: 64
Study: 16325899

Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) for non-cancer subjects
Number of subjects: 617

Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS) for non-cancer subjects
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) for females
Number of subjects: 617

Group type: COMPARATOR
Intervention: Follow-up smoking status group (FS) for females
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Biomarker feedback group (BF) with risky genotype
Number of subjects: 617
Study: 14719211

Group type: EXPERIMENTAL
Intervention: Combination therapy of 2 drugs (rifampicin + cotrimoxazole or doxycycline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combination of 3 drugs (streptomycin + rifampicin + doxycycline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment duration of 5 months or less
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Treatment duration of more than 5 months
Number of subjects: 90
Study: 10758521

Group type: EXPERIMENTAL
Intervention: Bed Positioning Program (BPP) for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: No intervention (control) for 8 weeks
Number of subjects: 16
Study: 8821516

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg, 3 times daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, 3 times daily for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg with 25 mg warfarin on Day 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with 25 mg warfarin on Day 4
Number of subjects: 0
Study: 1453585

Group type: EXPERIMENTAL
Intervention: Continuous cyclic peritoneal dialysis (CCPD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 16
Study: 3881309

Group type: EXPERIMENTAL
Intervention: Metoclopramide (two 10-mg capsules t.i.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 8
Study: 31288925

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: All Others (AO)
Number of subjects: 18
Study: 29678170

Group type: EXPERIMENTAL
Intervention: Suture repair group with dynamic augmentation and microfracture of the femoral notch
Number of subjects: 48

Group type: COMPARATOR
Intervention: ACL reconstruction group with autologous semitendinosis graft and all-inside technique
Number of subjects: 48
Study: 27055679

Group type: EXPERIMENTAL
Intervention: 3% diquafosol sodium ophthalmic solution (DQS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DQS
Number of subjects: 17

Group type: COMPARATOR
Intervention: AT
Number of subjects: 17
Study: 25041069

Group type: EXPERIMENTAL
Intervention: Alcohol+energy drink condition
Number of subjects: 75

Group type: COMPARATOR
Intervention: Alcohol-only condition
Number of subjects: 75
Study: 22167565

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) dosing strategies
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for VPA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Application of the pharmacokinetic model to SMA patients
Number of subjects: 52
Study: 20693880

Group type: EXPERIMENTAL
Intervention: Prone position (15 subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sitting position (15 subjects)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of CEPs between prone and sitting positions
Number of subjects: 30
Study: 18277195

Group type: EXPERIMENTAL
Intervention: Regular exercise training (ET)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Percutaneous intervention (PCI)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Event-free survival rates
Number of subjects: 101
Study: 16466165

Group type: EXPERIMENTAL
Intervention: Xiongshao Capsule (XSC)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 124
Study: 12933954

Group type: EXPERIMENTAL
Intervention: Splinting (wrist splint worn at night for at least six weeks)
Number of subjects: 89
Study: 10223781

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (oral contraceptives only)
Number of subjects: 12
Study: 8656328

Group type: EXPERIMENTAL
Intervention: Borderline personality disorder diagnosis
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Narcissistic personality disorder diagnosis
Number of subjects: 320
Study: 2083081

Group type: EXPERIMENTAL
Intervention: Dermoval cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone Aster à 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parfenac, indomethacin 2.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skinbase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colorimetric parameters a* (redness) and L* (luminance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transepidermal water loss
Number of subjects: 0
Study: 630211

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and prednisolone (combination chemotherapy)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlorambucil (single-agent chemotherapy)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both treatments (combination and single-agent chemotherapy)
Number of subjects: 66
Study: 30929590

Group type: EXPERIMENTAL
Intervention: Art Therapy (AT) for eight weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham Art Therapy (mandala coloring group) for eight weeks
Number of subjects: 20
Study: 29137028

Group type: EXPERIMENTAL
Intervention: CABPB with positioning posterior cord guided by nerve stimulator (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CABPB guided by ultrasound (group B)
Number of subjects: 80
Study: 26040317

Group type: EXPERIMENTAL
Intervention: Water-aided insertion and air insufflation during withdrawal
Number of subjects: 92

Group type: COMPARATOR
Intervention: Air insufflation during both insertion and withdrawal
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Water-aided insertion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 92
Study: 23351071

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) therapy
Number of subjects: 36
Study: 21572373

Group type: EXPERIMENTAL
Intervention: PHiD-CV (2 + 1)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: PHiD-CV (3 + 1)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (unprimed)
Number of subjects: 172
Study: 18313881

Group type: EXPERIMENTAL
Intervention: 5-FU-based treatment
Number of subjects: 855
Study: 16504835

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA1c quartiles (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables (age, duration of diabetes, insulin use, smoking history, hypertension, BMI, race, ethnicity, cholesterol levels, statin use)
Number of subjects: 0
Study: 12946547

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg QD for 12 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Candesartan 16 mg QD for 12 months
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Perindopril and Candesartan (both groups)
Number of subjects: 96
Study: 11559960

Group type: EXPERIMENTAL
Intervention: MDMA (1.7 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10086826

Group type: EXPERIMENTAL
Intervention: Quit smoking at some point during the first year and stayed quit
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Smoked intermittently during the study
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Continued to smoke throughout the study
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Several attempts to quit smoking
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Quitting smoking for an interval followed by relapse to smoking
Number of subjects: 5887
Study: 7994166

Group type: EXPERIMENTAL
Intervention: Incremental intravenous infusion of adrenaline (low, intermediate, high doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 10
Study: 2544291

Group type: EXPERIMENTAL
Intervention: 2 mg intravenous GR43175
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19127179

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Change of Direction Speed (CODS) with Static Stretching (SS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 429499

Group type: EXPERIMENTAL
Intervention: 50 mg sulpiride orally twice a day during the first 7 days of the puerperium
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo orally twice a day during the first 7 days of the puerperium
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 50 mg sulpiride orally
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 31827679

Group type: EXPERIMENTAL
Intervention: Dynamic resistance training with elastic bands (TG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 29136343

Group type: EXPERIMENTAL
Intervention: MOD-4023 (2.5 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MOD-4023 (7.5 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MOD-4023 (15 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MOD-4023 (all doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 42
Study: 29297667

Group type: EXPERIMENTAL
Intervention: Facet fixation combined with interbody fusion (Cage 'Facet Wedge')
Number of subjects: 145

Group type: COMPARATOR
Intervention: Pedicle screw installation after open decompression and interbody fusion (control group)
Number of subjects: 145
Study: 24138460

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21809149

Group type: EXPERIMENTAL
Intervention: CTC intervention communities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 24
Study: 20079166

Group type: EXPERIMENTAL
Intervention: Nevirapine-based HAART
Number of subjects: 198
Study: 17488174

Group type: EXPERIMENTAL
Intervention: Orff-based music therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Social work
Number of subjects: 26

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 26
Study: 15207890

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly for 4 weeks followed by alendronate 10 mg once daily for 4 weeks
Number of subjects: 406
Study: 11920985

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with exposure-based behavior therapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) with nonexposure-based behavior therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pretreatment cue reactivity
Number of subjects: 135
Study: 9760611

Group type: EXPERIMENTAL
Intervention: Capsule-bending ring
Number of subjects: 100

Group type: COMPARATOR
Intervention: No capsule-bending ring (Control)
Number of subjects: 100
Study: 8638858

Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 2655451

Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 313

Group type: COMPARATOR
Intervention: Ortho‐Novum 7/7/7
Number of subjects: 313

Group type: COMPARATOR
Intervention: Tri‐Norinyl
Number of subjects: 313
Study: 798194

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1200 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30894208

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w + MTX
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w + MTX
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo switching to Sarilumab 150 mg q2w + MTX
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo switching to Sarilumab 200 mg q2w + MTX
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo to Sarilumab 150 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo to Sarilumab 200 mg
Number of subjects: 243
Study: 28678854

Group type: EXPERIMENTAL
Intervention: Educational booklet on peri-TKA management
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard information by the surgeon
Number of subjects: 42
Study: 25752969

Group type: EXPERIMENTAL
Intervention: six‐day, multidimensional residential rehabilitation course
Number of subjects: 507

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 507
Study: 23511065

Group type: EXPERIMENTAL
Intervention: Quit Now
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Quit Later
Number of subjects: 1132
Study: 21751181

Group type: EXPERIMENTAL
Intervention: SDD (polymyxin B sulphate, tobramycin and amphotericin)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 19428923

Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine with Alhydrogel
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (comparator)
Number of subjects: 300
Study: 16728245

Group type: EXPERIMENTAL
Intervention: Glass ionomer cements (GIC) and resin modified glass ionomer cements (RMGIC) stored in water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: GIC and RMGIC cements stored in mineral oil
Number of subjects: 0
Study: 15572868

Group type: EXPERIMENTAL
Intervention: Calendula officinalis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ferrum muriaticum
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11060532

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687
Study: 9069476

Group type: EXPERIMENTAL
Intervention: Prothrombotic abnormalities in patients with BIH
Number of subjects: 38
Study: 9590971

Group type: EXPERIMENTAL
Intervention: Diclofenac‐potassium 50 mg
Number of subjects: 109

Group type: COMPARATOR
Intervention: Glafenine 200 mg
Number of subjects: 109
Study: 3513588

Group type: EXPERIMENTAL
Intervention: Dexamethasone administration
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 250